Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2018-12-17

Clinical Trial Update: Prevention of Delayed Graft Function Using Eculizumab Therapy (PROTECT Study) [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 trial updating on prevention of delayed graft function with eculizumab therapy; study completed with results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Eculizumab (eculizumab)

Snippet

Sponsor: Alexion Pharmaceuticals, Inc. | Conditions: Delayed Graft Function | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2018-12-17